Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare, complex, multisystem disease of dysregulated complement activity, characterized by progressive thrombotic microangiopathy (TMA), acute kidney injury, and multiorgan dysfunction, which often progresses to chronic kidney disease. Resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbour, Thomas, Scully, Marie, Ariceta, Gema, Cataland, Spero, Garlo, Katherine, Heyne, Nils, Luque, Yosu, Menne, Jan, Miyakawa, Yoshitaka, Yoon, Sung-Soo, Kavanagh, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207473/
https://www.ncbi.nlm.nih.gov/pubmed/34169200
http://dx.doi.org/10.1016/j.ekir.2021.03.884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207473/
https://www.ncbi.nlm.nih.gov/pubmed/34169200
http://dx.doi.org/10.1016/j.ekir.2021.03.884

Ejemplares similares